Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ZEDIRA GmbH logo — Targeting Transglutaminase for Research & Medicine! ZED1227...

ZEDIRA GmbH

Targeting Transglutaminase for Research & Medicine! ZED1227 First Tissue Transglutaminase Inhibitor in Clinical Trials!

Founded 2007 Germany Darmstadt, Germany 10 employees Grant Total: $1.50M Biotechnology, Health Care +1

General Information

Company Name ZEDIRA GmbH
Founded Year 2007
Location Germany Darmstadt, Germany
Employees 10
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with ZEDIRA GmbH. To contact ZEDIRA GmbH, visit zedira.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ZEDIRA GmbH compare?

A PDF of ZEDIRA GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ZEDIRA GmbH soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ZEDIRA GmbH

ZEDIRA GmbH is a global brand specializing in transglutaminase, with a focus on developing innovative products and solutions for research and medicine. Founded in 2007 and headquartered in Germany, Zedira has become a leader in the biotechnology, health care, and pharmaceutical industries. The company offers over 200 specialty reagents for transglutaminase-related R&D, catering to researchers from academia and industry, including 12 of the top 15 big pharma companies. Zedira's cutting-edge products and customized services have gained increasing traction within the scientific community. Zedira's latest product field focuses on solutions for site-specific labeling of proteins using transglutaminases, showcasing their commitment to advancing research and development in this niche area. In November 2016, Zedira secured a substantial €1.50M grant investment from the German Federal Ministry of Education and Research to further support their pioneering work in transglutaminase research and development. With their innovative approach and strong support from investors, Zedira is well-positioned to make significant strides in its mission of targeting transglutaminase for research and medicine, particularly with the ongoing ZED1227 First Tissue Transglutaminase Inhibitor in Clinical Trials.

Business keywords: Biotech company, Transglutaminase research, Clinical trials, Specialty reagents, Neurological disorders, Celiac disease, Diagnostics, Proteases, Assays, Antibodies, Inhibitors, ELISA-Kits, Drug discovery, Research and development, Hessen, Germany

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €1.50M 1
German Federal Ministry of Education and Research
30 Nov 2016
Seed Round Undisclosed 1
HTGF | High-Tech Gruenderfonds
18 May 2010

ZEDIRA GmbH Alternatives & Competitors

View All Alternatives
ZEDIRA GmbH vs
Asceneuron SA
Asceneuron SA Switzerland

Targeting the root cause of neurodegeneration

Series C
20 employees
Biotechnology, Health Care
ZEDIRA GmbH vs
MBL International Corporation
MBL International Corporation United States

MBL International provides high-quality products and solutions to advance life science research.

83 employees
Biotechnology, Health Care
ZEDIRA GmbH vs
Cepham Life Sciences, Inc.
Cepham Life Sciences, Inc. United States

Develop and manufacture wide range of products in the areas of Proteomics, Molecular Biology & Drug...

4 employees
Biotechnology, Health Care
View all alternatives

FAQ About ZEDIRA GmbH

Targeting Transglutaminase for Research & Medicine! ZED1227 First Tissue Transglutaminase Inhibitor in Clinical Trials!
ZEDIRA GmbH was founded in 2007.
ZEDIRA GmbH is headquartered in Darmstadt, Germany.
ZEDIRA GmbH operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Biotech company, Transglutaminase research, Clinical trials and Specialty reagents.
ZEDIRA GmbH has approximately 10 employees.
ZEDIRA GmbH has completed 2 funding rounds, raising a total of $1.50M. The latest funding stage is Grant.
Top alternatives and competitors to ZEDIRA GmbH include Asceneuron SA, MBL International Corporation, Cepham Life Sciences, Inc., Drug Discovery & Development, Cancer Research Horizons. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ZEDIRA GmbH and Asceneuron SA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ZEDIRA GmbH, https://bouncewatch.com/company/zedira-gmbh, updated 29 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout